Transient Myeloproliferative Disorder in a Neonate without Down Syndrome—A Rare Case Report and Review of the Literature

Abstract

Transient myeloproliferative disorder (TMD) is a self-limiting disorder characteristically seen in neonates with Down syndrome with or without somatic mosaicism. Trisomy-21 limited to the hematopoietic lineage alone has been described; awareness of which is very important for appropriate evaluation and counseling in phenotypically normal children.

We report a newborn with TMD who presented at birth with intracranial bleed secondary to thrombocytopenia. Peripheral smear showed 10% blasts and flow cytometry further revealed myeloid blasts of megakaryocytic lineage. The child had no phenotypic features of Down syndrome.

Cytogenetic analysis (fluorescence in situ hybridization) and the conventional karyotyping from peripheral blood showed trisomy-21 in blast cells and the findings completely cleared with peripheral clearance of blasts. The possibility of Down syndrome with mosaicism was considered, however, repeat conventional karyotyping from peripheral blood at D36 and D60 of life was normal, suggesting the gain of chromosome 21 was restricted to the TMD clones.

The child was supported with irradiated platelet transfusions and adequate hydration. Spontaneous resolution with resolution of cytopenias and peripheral clearance of blasts were noted from D10 of life. The child is neurologically normal and growing well.

Very few reports of TMD in newborn babies without Down syndrome have been described in the literature. Awareness about the diagnostic entity of TMD even without Down syndrome would help in appropriate management and counseling.

Keywords

congenital leukemia - Down syndrome - mosaicism - transient abnormal myelopoiesis - case report

Disclosures

• The authors have no relevant financial or nonfinancial interests to disclose.

• The authors have no competing interests to declare that are relevant to the content of this article.

• All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or nonfinancial interest in the subject matter or materials discussed in this manuscript.

• There are no prior publications or submissions with any overlapping information, including studies and patients.

Declaration of Patient Consent

Appropriate informed consent from parents of the child has been obtained.

Publication History

Article published online:
22 May 2024

• References

• 1 Apollonsky N, Shende A, Ouansafi I, Brody J, Atlas M, Aygun B. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes. J Pediatr Hematol Oncol 2008; 30 (11) 860-864
• 2 Baca N, Sanchez-Lara PA, Schreck R, Eno CC, Majlessipour F. Transient myeloproliferative disorder as the presenting feature for mosaic trisomy 21. Cold Spring Harb Mol Case Stud 2021; 7 (06) a006126
• 3 Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113 (12) 2619-2628
• 4 Gamis AS, Alonzo TA, Gerbing RB. et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood 2011; 118 (26) 6752-6759 , quiz 6996
• 5 Papavassiliou P, Charalsawadi C, Rafferty K, Jackson-Cook C. Mosaicism for trisomy 21: a review. Am J Med Genet A 2015; 167A (01) 26-39
• 6 Tsai MH, Hou JW, Yang CP. et al. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome. Indian J Pediatr 2011; 78 (07) 826-832
• 7 Alford KA, Reinhardt K, Garnett C. et al; International Myeloid Leukemia-Down Syndrome Study Group. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 2011; 118 (08) 2222-2238
• 8 Roy A, Roberts I, Norton A, Vyas P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol 2009; 147 (01) 3-12
• 9 Rozen L, Huybrechts S, Dedeken L. et al. Transient leukemia in a newborn without Down syndrome: case report and review of the literature. Eur J Pediatr 2014; 173 (12) 1643-1647
• 10 Magalhães IQ, Splendore A, Emerenciano M. et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol 2005; 27 (01) 50-52
• 11 Bertrums EJ, Buijs A, van Grotel M. et al. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease. Pediatr Blood Cancer 2017; 64 (03) 1-4
• 12 De Rooij MDJ, Masetti MDR, van den Heuvel-Eibrink MM. et al. Prognostic relevance of recurrent genetic aberrations in pediatric acute megakaryoblastic leukemia. Blood 2015; 126: 2598
• 13 Sheltzer JM, Amon A. The aneuploidy paradox: costs and benefits of an incorrect karyotype. Trends Genet 2011; 27 (11) 446-453
• 14 Kato K, Matsui K, Hoshino M. et al. Tumor cell lysis syndrome resulting from transient abnormal myelopoiesis in a neonate with Down's syndrome. Pediatr Int 2001; 43 (01) 84-86
• 15 Massey GV, Zipursky A, Chang MN. et al; Children's Oncology Group (COG). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006; 107 (12) 4606-4613
• 16 Cushing T, Clericuzio CL, Wilson CS. et al. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr 2006; 148 (05) 687-689
• 17 Brissette MD, Duval-Arnould BJ, Gordon BG, Cotelingam JD. Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without Down syndrome. Am J Hematol 1994; 47 (04) 316-319